The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

BACKGROUND: We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC). PATIENTS AND METHODS: A total of 379 eligible women with estrogen receptor positive (ER+), HER2-negative EBC and 0–3 positive lymph nodes w...

Descripción completa

Detalles Bibliográficos
Autores principales: Eiermann, W., Rezai, M., Kümmel, S., Kühn, T., Warm, M., Friedrichs, K., Schneeweiss, A., Markmann, S., Eggemann, H., Hilfrich, J., Jackisch, C., Witzel, I., Eidtmann, H., Bachinger, A., Hell, S., Blohmer, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574549/
https://www.ncbi.nlm.nih.gov/pubmed/23136233
http://dx.doi.org/10.1093/annonc/mds512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574549/
https://www.ncbi.nlm.nih.gov/pubmed/23136233
http://dx.doi.org/10.1093/annonc/mds512

Ejemplares similares